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questionnaires that were not based on patient interviews. The 25
and 18 item RMDQ is a measure of pain and function widely
used in low back pain (LBP) trials that was based solely on clin-
ician involvement. METHODS: Two US focus groups (n = 15)
and one UK focus group (n = 7) were asked to complete the
problem elicitation technique (PET) alongside the RMDQ to
determine the relevance of items. The PET measures the impor-
tance of concepts based on a series of questions rating the impor-
tance of each item on a ﬁve-point likert response continuum. To
ensure the RMDQ was not missing any relevant items partici-
pants were asked several open-ended questions. RESULTS: Par-
ticipants conﬁrmed the content validity of the RMDQ by
identifying four areas of importance: pain/discomfort, activities
of daily living, sleep problems and emotional impact. Based on
the PET, all RMDQ items were rated as moderately to extremely
important (item score range of 3.57–4.36 on a one—ﬁve scale).
Items rated least important were the same items removed in the
18 item version. In the open ended questions, sleep disturbances
was consistently mentioned as a primary area of concern. CON-
CLUSIONS: The PET augmented by open-ended questions is a
valid method for conﬁrming the content validity of question-
naires that did not include patient involvement in their develop-
ment. These ﬁndings support the continued use of the RMDQ
in LBP trials; however, consideration should be given to includ-
ing additional sleep questions or measuring this concept 
separately.
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QUALITY OF LIFE IN ASTHMA PATIENTS IS AFFECTED BY
HOME TELEMANAGEMENT
Joshi A,Amelung P, Finkelstein J
University of Maryland, Baltimore, MD, USA
OBJECTIVES: To determine whether Home Automated Telem-
anagement (HAT) affects disease-speciﬁc Quality of Life (QOL)
in adult asthma patients. METHODS: Fifty adult patients with
mild persistent to severe asthma were randomly assigned to an
intervention or control group and were followed for 12 months.
The patients in the control group received regular care. The
patients in the intervention group used HAT to monitor and
manage their condition. The HAT system assisted clinicians in
setting up individualized action plans and helped asthma patients
in following their action plans at home using peak ﬂow meter
and a laptop connected with a hospital. RESULTS: Both inter-
vention and control group patients had similar baseline demo-
graphic characteristics with regard to their asthma severity,
action plan use, computer skills and the quality of life. After 12-
month follow-up the mean total QOL score in the intervention
and the control group was 20.2 ± 0.9 and 16.9 ± 1.3 respec-
tively. The difference was signiﬁcant (p < 0.0001) at the alpha
level of 0.05. Analysis of the symptoms domain of the asthma
quality of life showed improved score 5.3 ± 0.4 in the interven-
tion group compared to the control group 4.4 ± 0.6 (p < 0.05).
The activities domain of the QOL showed an improvement in
the activities in the intervention group 5.1 ± 0.2 compared to the
control group 3.7 ± 0.3 (p < 0.05). There was a statistically sig-
niﬁcant difference (p < 0.05) in the emotions domain of the
QOL: the mean score in the intervention group was 4.8 ± 0.2
whereas the mean score in the control group was 4.4 ± 0.4. The
environment domain in the intervention group was 5.1 ± 0.3
compared to 4.4 ± 0.5 in the control group (p < 0.005). CON-
CLUSION: Disease-speciﬁc quality of life in asthma patients is
positively affected by Home Telemanagement.
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ASSESSING HEALTH-RELATED QUALITY OF LIFE USING THE
SF-12V2 FOR PATIENTS WITH CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
Martinez FJ1, Raczek AE2, DeRosa MA2, Girts TK3, Phillips AL3
1University of Michigan, Ann Arbor, MI, USA; 2QualityMetric
Incorporated, Lincoln, RI, USA; 3Boehringer Ingelheim, Ridgeﬁeld, CT,
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OBJECTIVES: To assess health-related quality-of-life (HRQOL)
for patients with chronic obstructive pulmonary disease (COPD).
METHODS: In Spring 2004, 700 patients cared for by pulmo-
nologists or general practitioners at 12 sites across the US com-
pleted a 90-item survey that included the SF-12v2 and
pre-/post-bronchodilator spirometry. COPD was deﬁned as post-
bronchodilator Forced Expiratory Volume in one second/Forced
Vital Capacity (FEV1/FVC) <70%. Descriptive statistics for SF-
12v2 measures were calculated for mild (FEV1 >80% predicted)
and moderate/severe (FEV1 <80% predicted) COPD. Disease
burden was estimated by adjusting general population norma-
tive data from the 1998 National Survey of Functional Health
Status (NSFHS) to age and sex characteristics of the COPD
sample. Multivariate and univariate analyses of variance
(MANOVA, ANOVA) F-statistics were used to test for differ-
ences between patients’ HRQOL and adjusted norms. RESULTS:
Based on spirometry, 36% (N = 249) of patients had COPD
(20% mild, 80% moderate/severe). Patients with COPD were
less likely to describe their health as very good or excellent
(20.5% vs. 36.8%, p < 0.001), and more likely to describe their
health as fair or poor (33.3% vs. 23.4%, p < 0.005) compared
to those without COPD. MANOVA revealed a signiﬁcant dif-
ference between the full proﬁle of SF-12v2 scales for COPD
patients and the US general population (p < 0.001). Adjusted
norm comparisons revealed that patients with mild COPD had
signiﬁcantly lower (mean, SD) Role Physical (41.9, 11.1; p <
0.02) and Physical Component Summary (PCS) (41.0, 12.0; p <
0.02) scores. Moderate/severe COPD patients had large, statisti-
cally signiﬁcant decrements across all SF-12v2 measures. Differ-
ences from normative values were most notable for Physical
Functioning (38.2, 12.8; p < 0.001), PCS (38.9, 11.7; p < 0.001),
Role Physical (39.7, 11.9; p < 0.001), General Health (40.8,
11.2; p < 0.001), and Role Emotional (43.0, 13.0; p < 0.001).
CONCLUSION: Compared to the US general population,
COPD has a signiﬁcant impact on a patient’s HRQOL, notable
with mild disease and pronounced at higher severity levels.
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ESTIMATING THE COST-EFFECTIVENESS OF FLUTICASONE
PROPIONATE FOR TREATING CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
Briggs A1,Wang H2, Gagnon YM2, Spencer S3, Bale G4, Spencer M5,
Burge S4
1University of Oxford, Oxford, United Kingdom; 2Oxford Outcomes
(Canada) Ltd,Vancouver, BC, Canada; 3Brunel University, Uxbridge,
UK 4Birmingham Heartlands Hospital, Birmingham, UK;
5GlaxoSmithKline, London, UK
OBJECTIVES: To explore the cost-effectiveness of ﬂuticasone
propionate (FP) for the treatment of chronic obstructive pul-
monary disease (COPD), we estimated costs and quality adjusted
life years (QALYs) over three-years, based on an economic
appraisal of a previously reported clinical trial (ISOLDE).
METHODS: Results from the initial analyses of the trial data
showed signiﬁcant improvements with FP in reducing the rate of
exacerbations from COPD, in slowing the rate of decline in
health status and a trend towards improved survival. A recently
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published algorithm for the SF-36 generic instrument allowed the
calculation of utility scores for quality of life suitable for calcu-
lating QALYs. Standard statistical techniques, including multiple
imputation approaches to handle missing data, were employed
to address missing data issues allowing the estimation of cumu-
lative costs and QALYs over the three year study period.
RESULTS: In the base case analysis we estimated the incremen-
tal costs of FP versus placebo to be GBP929 (95% conﬁdence
interval (CI): GBP633 to 1220) with an additional effect of 0.14
QALYs (CI: 0.07 to 0.20). This generates a cost-effectiveness
estimate for the within-trial period of GBP6830 per QALY
gained (CI: GBP3960 to 13,300/QALY gained) which includes
uncertainty due to the imputation process. An alternative impu-
tation approach did not materially affect this estimate. CON-
CLUSIONS: Previous analyses of the ISOLDE study showed
signiﬁcant improvement on disease speciﬁc health status mea-
sures and a trend towards a survival advantage for treatment
with FP. This analysis shows that joint considerations of quality
of life and survival result in a substantial increase in QALYs in
favor of FP. Based on these data, FP appears cost-effective.
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PRESCRIBING PATTERNS IN AMBULATORY CARE CENTERS
FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY
DISEASE (COPD)
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Chronic obstructive pulmonary disease (COPD) is primarily a
disease of the elderly with increasing worldwide morbidity and
mortality. Goals of treatment are to relieve symptoms, reduce
airﬂow obstruction, and improve functioning. Although current
treatment strategies and guidelines for long-term COPD man-
agement recognize bronchodilators as ﬁrst-line therapy for all
patients, inhaled corticosteroids are prescribed for some patients.
OBJECTIVE: To characterize COPD medication prescribing pat-
terns among visits of patients >=65y across US ambulatory care
centers. METHODS: Data from the 2002 National Ambulatory
Medical Care Survey and the National Hospital Ambulatory
Medical Care Survey gathered from physician ofﬁces, hospital
outpatient, and emergency departments were analyzed for
patients >=65y. COPD visits were identiﬁed by primary diag-
noses of bronchitis, chronic bronchitis, emphysema, or chronic
airway obstruction. Patients with coexisting asthma were
excluded. Sample data were weighted to provide national esti-
mates. RESULTS: In 2002, COPD accounted for 7.7 million
ambulatory care visits among patients >=65y. Of these visits,
54.6% were by females and 93.0% were by white patients.
COPD medications were prescribed at 38.7% of visits with 
an average of 1.8 COPD medications prescribed per visit. 
Bronchodilators, alone or in combination, were prescribed at 
2.0 million visits, representing 26.5% of visits. Prescribed 
bronchodilators were short-acting beta-agonists (16.4%), anti-
cholinergics (11.8%), methylxanthines (7.5%) and long-
acting beta-agonists (4.8%). Inhaled corticosteroids, alone or in
combination, were prescribed at 13.4% of visits. The most 
commonly prescribed COPD medication combination was 
short-acting beta-agonists with anticholinergics (6.9%). CON-
CLUSION: Ambulatory care center prescribing patterns suggest
that COPD medications may be under-prescribed in elderly
patients. Bronchodilators appear to be the most common COPD-
speciﬁc treatment. The frequency with which short-acting beta-
agonists and anticholinergics were prescribed concurrently in
this dataset may indicate a deﬁciency in acceptable therapies that
provide sufﬁcient bronchoconstriction relief. Further research is
needed to assess optimization of drug management for elderly
COPD patients.
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DISCRETE EVENT SIMULATION TO ESTIMATE COST-BENEFIT
OF PREVENTING SUDDEN CARDIAC DEATHS WITH AN
IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) VS.
AMIODARONE IN FRANCE
Deniz HB, Caro JJ,Ward AJ
Caro Research, Concord, MA, USA
OBJECTIVE: Until recently, primary prevention of sudden
cardiac death depended on anti-arrhythmic drugs. The SCD-
HeFT Trial conﬁrmed the efﬁcacy of ICD, as all-cause mortality
was decreased 23% versus placebo. Estimating lives saved and
economic impact of primary prevention of sudden cardiac death
with an ICD versus amiodarone in France was the object of this
study. METHODS: A discrete event simulation was developed
to estimate effects over three years. Identical patients received
either device or amiodarone. Post-implantation complications
(lead and device-related) or toxicity from amiodarone could
arise. Model parameters and risk functions were developed based
on SCD-HeFT data, assuming life-threatening arrhythmia rates
and other death are not differential. Probability of death given
arrhythmia was 90% with amiodarone, 47% with ICD. To avoid
ageism inherent in QALYs, the economic value society places on
a life (5,697,127€) was derived from a meta-analysis and used
in cost-beneﬁt analyses. While estimates of the value of life vary
from country to country, this value reﬂects a recent average for
European countries. Costs are reported in 2004 € and discounted
at 3%. In total, 100 replications of 1000 identical twin pairs
were run. Sensitivity analyses were performed for key input para-
meters. RESULTS: ICD use in 1000 patients was predicted to
prevent 62 premature deaths over three years. Total additional
costs accrued were 20,121€ per patient. The cost/beneﬁt ratio
was 0.06 which means for every 1€ gained, 0.06€ has to be
invested. In 55% of the replications ICD dominates Amiodarone.
Investment in ICD is worthwhile whenever society values a life
at more than 325,000€. CONCLUSION: ICDs increase imme-
diate costs but their use is consistent with the value of life esti-
mated in Western societies.
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LIPID LEVELS AND NCEP ATP-III LDL-CHOLESTEROL GOAL
ATTAINMENT IN PATIENTS NEWLY-INITIATED ON
ROSUVASTATIN OR ATORVASTATIN
Bullano MF1, Kamat SA1,Williams SA2,Wertz DA1, Cziraky MJ1,
Willey VJ1
1HealthCore, Inc, Wilmington, DE, USA; 2AstraZeneca, Wilmington,
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OBJECTIVE: To compare effectiveness of rosuvastatin to ator-
vastatin on lipid levels (LDL-C, HDL-C, triglycerides, total 
cholesterol) and LDL-C goal attainment. METHODS: Patients
newly-initiated on rosuvastatin or atorvastatin between August
1, 2003 and June 30, 2004 were identiﬁed from a West Coast
health plan’s claims data for this retrospective, longitudinal
cohort study. Patients were excluded if they had any dyslipidemic
therapy 12-months preceding their initial statin ﬁll. Propensity
score matching on baseline characteristics was used to minimize
